Clinical trial
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due…
NCT00332696 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00332696 |
|---|---|
| Title | Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis |
| Official title | Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis |
| Intervention type | Drug |
| Interventions | Octreotide LAR, Octreotide (Immediate release), methylprednisolone, Placebo |
| Enrollment | 64 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jun 2, 2006 |
| Last update posted | Sep 23, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: